Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach

References

• Agid O, Foussias G, Remington G. 2010. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 11:2301–2317.
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, Toumi M, Brugha T. 2004. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184:346–351.
   PubMed Web of Science ®Google Scholar
• Alvarez Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. 2012. Risk factors for relapse following treatment for first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139:116–128.
   PubMedGoogle Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449.
   PubMed Web of Science ®Google Scholar
• Ayuso-Gutiérrez JL, del Río Vega JM. 1997. Factors influencing relapse in long-term course of schizophrenia. Schizophr Res 28:199–206.
   PubMed Web of Science ®Google Scholar
• Burns T, Fiander M, Audini B. 2000. A Delphi approach to characterising ‘relapse’ and used in UK clinical practice. Int J Soc Psychiatry 46:220–230.
   PubMed Web of Science ®Google Scholar
• Bustillo J, Buchanan RW, Carpenter WT Jr. 1995. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Scizhophr Bull 21:553–559.
   PubMedGoogle Scholar
• Chabungbam G, Avasthi A, Sharan P. 2007. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 61:587–593.
   PubMed Web of Science ®Google Scholar
• Csernansky J, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16–22.
   PubMed Web of Science ®Google Scholar
• Dalkey N, Brown B, Cochran S. 1969. The Delphi method, III: use of self ratings to improve group estimates. Santa Monica, CA: Rand Corp. Publication RM-6115-PR.
   Google Scholar
• Dilla T, Ciudad A, Alvarez M. 2013. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence 7:275–284.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, Harvey BH. 2013. The nature of relapse in schizophrenia. BMC Psychiatry 13:50.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen PP, Koen L, Niehaus DJH, Martinez G. 2012. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-yer open-label clinical study. J Clin Psychiatry 73:e541–e547.
   PubMedGoogle Scholar
• Fiander M, Burns T. 1998. Essential components of schizophrenic care: a Delphi approach. Acta Psychiatr Scand 98: 400–405.
   PubMed Web of Science ®Google Scholar
• Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. 2010. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 119:79–88.
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. 2013. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3:200–18.
   PubMedGoogle Scholar
• Hong J, Windmeijer F, Novick D, Haro JM, Brown J. 2009. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 33:835–841.
   PubMed Web of Science ®Google Scholar
• Karow A, Moritz S, Lambert M, Schöttle D, Naber D. 2012. Remitted but still impaired? Symptomatic versus functional remission with schizophrenia. Eur Psychiatry 27:401–405.
   Google Scholar
• Koening M, Casyillo MC, Urdapilleta I, le Borgne P, Bouleau JH. 2011. Relapse in schizophrenia: an exploratory study of the joint conceptions of patients: parents and caregivers. [Article in French]. Encephale 37:207–216.
   PubMedGoogle Scholar
• Lader M. 1995. What is relapse in schizophrenia? Int Clin Psychopharmacol 9:5–9.
   PubMed Web of Science ®Google Scholar
• Lader M. 1998. Pharmacological prevention of relapse. Kaohsiung J Med Sci 14:448–457.
   PubMedGoogle Scholar
• Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS. 2013. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 16:1290–1299.
   PubMedGoogle Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222.
   PubMed Web of Science ®Google Scholar
• Morrison AP, Barratt S. 2010. What are the components of CBT for psychosis? A Delphi study. Schizophr Bull 36:136–142.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Sermon J, Hemels M, Schreiner A. 2013. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry 12:32.
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247.
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Cavallaro R, Folnegović-Šmalc V, Bidzan L, Emin Ceylan M, Schreiner A. 2013. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol 3:191–199.
   PubMedGoogle Scholar
• Thomas P. 2013. Relapse: causes and consequences. [Article in French]. Encephale 39:S79–S82.
   Google Scholar
• Wunderink L, Nienhuis FJ, Sytema S, Slooff C, Knegtering R, Wiersma D. 2007. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68:654–661.
   PubMed Web of Science ®Google Scholar
• Zubin J, Steinhauer SR, Condray R. 1992. Vulnerability to relapse in schizophrenia. Br J Psychiatry 161:13–18.
   Google Scholar